Page 35 - Read Online

These results were confirmed by Hosokawa et al. who chemoembolization. Aliment Pharmacol Ther 2008;27:1253-60.
[25]
suggested that glycemic control in diabetic patients, more 13. Hagihara H, Nouso K, Kobayashi Y, Iwasaki Y, Nakamura S, Kuwaki K,
so than diabetes itself, plays a role in the survival. The Toshimori J, Miyatake H, Ohnishi H, Shiraha H, Yamamoto K. Effect
of pegylated interferon therapy on intrahepatic recurrence after curative
mechanism by which glycemic control and survival are related treatment of hepatitis C virus-related hepatocellular carcinoma.
is unknown, but frequent recurrence of HCC in hyperglycemic Int J Clin Oncol 2011;16:210-20.
patients and the accumulation of damage in liver function 14. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis:
because of repeated treatment intervention for HCC may interferon-alpha prevents the recurrence after curative treatment of hepatitis
C virus-related hepatocellular carcinoma. J Viral Hepat 2010;17:287-92.
lead to worsening survival. Diabetes accelerates liver fibrosis 15. Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong CN,
and inflammation with increased inflammatory markers and Wong J, Lee KF, Lai PB, Chan HL. Meta-analysis: the effi cacy of
cytokines resulting in severe liver failure and poor cancer anti-viral therapy in prevention of recurrence after curative treatment of
prognosis. [25] chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol
Ther 2011;33:1104-12.
16. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes
In conclusion, inadequate maintenance of blood glucose in mellitus and the risk of cancer: results from a large-scale population-based
diabetic patients is a significant risk factor for recurrence cohort study in Japan. Arch Intern Med 2006;166:1871-7.
of HCC and for poor survival after curative RFA therapy in 17. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P,
CHC patients. Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M.
Expanding the natural history of nonalcoholic steatohepatitis: from
cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology
REFERENCES 2002;123:134-40.
18. Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S,
Tanikawa M, Sone Y, Hisanaga Y. Impact of diabetes mellitus on
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.
CA Cancer J Clin 2005;55:74-108. the prognosis of patients with hepatocellular carcinoma. Cancer
2. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide 2001;91:957-63.
incidence and trends. Gastroenterology 2004;127:S5-16. 19. Huo TI, Wu JC, Lui WY, Huang YH, Lee PC, Chiang JH, Chang FY,
3. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Lee SD. Differential mechanism and prognostic impact of diabetes
Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. mellitus on patients with hepatocellular carcinoma undergoing surgical
World J Gastroenterol 2008;14:4300-8. and nonsurgical treatment. Am J Gastroenterol 2004;99:1479-87.
4. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, 20. Komura T, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K,
Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M. Management Yamashita T, Ohta T, Shimizu K, Nakamoto Y, Honda M, Takamura T,
of hepatocellular carcinoma: Report of Consensus Meeting in the Kaneko S. Impact of diabetes on recurrence of hepatocellular
45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol carcinoma after surgical treatment in patients with viral hepatitis. Am J
Res 2010;40:667-85. Gastroenterol 2007;102:1939-46.
5. Minami Y, Kudo M. Radiofrequency ablation of hepatocellular 21. Chen WT, Macatula TC, Lin CC, Lin CJ, Lin SM. Diabetes may not affect
carcinoma: current status. World J Radiol 2010;2:417-24. outcomes in hepatocellular carcinoma after radio-frequency ablation.
6. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Hepatogastroenterology 2011;58:551-7.
Lau WY. A prospective randomized trial comparing percutaneous 22. Aizawa N, Enomoto H, Imanishi H, Saito M, Iwata Y, Tanaka H,
local ablative therapy and partial hepatectomy for small hepatocellular Ikeda N, Sakai Y, Takashima T, Iwai T, Moriwaki E, Shimomura S,
carcinoma. Ann Surg 2006;243:321-8. Iijima H, Nakamura H, Nishiguchi S. Elevation of the glycated albumin
7. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, to glycated hemoglobin ratio during the progression of hepatitis C virus
Yoshida H, Kawabe T, Omata M. Percutaneous radiofrequency ablation related liver fi brosis. World J Hepatol 2012;4:11-7.
for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 23. American Diabetes Association. Diagnosis and classifi cation of diabetes
2005;103:1201-9. mellitus. Diabetes Care 2010;31:S62-9.
8. Izumi N, Asahina Y, Noguchi O, Uchihara M, Kanazawa N, Itakura J, 24. Youkou A, Hasegawa T, Suzuki K, Koya T, Sakagami T, Toyabe S,
Himeno Y, Miyake S, Sakai T, Enomoto N. Risk factors for distant Arakawa M, Gejyo F, Narita I, Suzuki E. Infl uence of obesity on control
recurrence of hepatocellular carcinoma in the liver after complete in asthmatic Japanese patients defi ned by the Japanese defi nition of
coagulation by microwave or radiofrequency ablation. Cancer obesity. Intern Med 2011;50:1911-6.
2001;91:949-56. 25. Hosokawa T, Kurosaki M, Tsuchiya K, Matsuda S, Muraoka M,
9. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Suzuki Y, Tamaki N, Yasui Y, Nakata T, Nishimura T, Suzuki S, Ueda K,
Radiofrequency ablation of hepatocellular cancer in 110 patients with Nakanishi H, Itakura J, Takahashi Y, Izumi N. Hyperglycemia is a
cirrhosis. Ann Surg 2000;232:381-91. signifi cant prognostic factor of hepatocellular carcinoma after curative
10. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence therapy. World J Gastroenterol 2013;19:249-57.
after curative resection of hepatocellular carcinoma: long-term results 26. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes
of treatment and prognostic factors. Ann Surg 1999;229:216-22. increases the risk of hepatocellular carcinoma in the United States: a
11. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and population based case control study. Gut 2005;54:533-9.
management of postoperative recurrence after resection of hepatocellular 27. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and
carcinoma. Ann Surg 2000;232:10-24. hepatocellular carcinoma: a cohort study in high prevalence area of
12. Fuke H, Sugimoto K, Shiraki K, Tanaka J, Beppu T, Yoneda K, hepatitis virus infection. Hepatology 2006;43:1295-302.
Yamamoto N, Ito K, Takaki H, Nakatsuka A, Yamakado K, Takeda K, 28. El-Serag HB, Hampel H, Javadi F. The association between diabetes
Takei Y. Predictive factors for distant recurrence of HCV-related and hepatocellular carcinoma: a systematic review of epidemiologic
hepatocellular carcinoma after radiofrequency ablation combined with evidence. Clin Gastroenterol Hepatol 2006;4:369-80.

28 Hepatoma Research | Volume 1 | Issue 1 | April 15, 2015